Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

Prime Editing has potential to be best-in-class approach for AATD ---- Previously undisclosed program now emerging from within liver platform; ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Shares of Prime Medicine ( PRME -0.25%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.

Acquired DNA mutations found in the SERPINA1 gene can protect liver cells from damage in patients with alpha-1 antitrypsin ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Prime Medicine, Inc. announced the launch of a preclinical program targeting alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting lung and liver function, utilizing their ...

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

Korro Bio, Inc. has completed dosing for the first two cohorts in its Phase 1/2a REWRITE clinical study of KRRO-110, aimed at treating Alpha-1 Antitrypsin Deficiency (AATD), with interim results ...

Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim ...